ClinicalTrials.gg
TerminatedNCT06079190PROGRESS-ADUpdated Sep 17, 2026

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

A Phase 2 interventional study of GSK4527226 and Placebo in Alzheimer's Disease, sponsored by GlaxoSmithKline. Terminated at 97 sites in 16 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early due to meeting pre-specified efficacy futility criteria at planned interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
367
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in Alzheimer Disease by GlaxoSmithKline — 2 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · GlaxoSmithKline.

Enrollment
12th of 34
367 · median 120
Started
2023
the only one that year
Phase 2
11 of 34
1 open now
Registered
32nd of 34
by date

Among the 34 studies in Alzheimer Disease by GlaxoSmithKline, this one is the 12th largest by enrollment, is the only one that started in 2023, is one of 11 in phase 2, and was the 32nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 34 studies in Alzheimer Disease by GlaxoSmithKline are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Alzheimer Disease by GlaxoSmithKline, or all of them as a file.
02

Study summary

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Mental Disorders
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participant must be in the Alzheimer's continuum as defined by the 2018 National Institute on Aging and Alzheimer's Association (NIAAA) Research Framework corresponding to the clinical categories of MCI due to AD and mild AD dementia.

Participant must have evidence of amyloid positivity either by positive positron emission tomography (PET) result (Amyloid PET scans must be read by a central imaging lab) or cerebrospinal fluid (CSF) amyloid beta (Aβ) test result indicative of amyloid positivity

  • Participants must also meet the following criteria for clinical severity:

    1. score of between 21 and 29 points
    2. CDR-global score (GS) of 0.5 to 1.0.
    3. CDR Memory Box score greater than or equal to (≥) 0.5.
    4. Participants with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale-IV Logical Memory II (WMS-IV LMII)
  • If the participant is receiving symptomatic AD medications such as an Acetylcholinesterase inhibitor (AChEI) or memantine, the dosing regimen must have been stable for at least 12 weeks prior to screening and is not expected to change during study participation.
  • If the participant is receiving other medications for AD related symptoms or associated conditions, the dosing regimen must have been stable for at least 4 weeks prior to screening and not expected to change during study participation. Symptoms must be considered adequately and stably controlled by the investigator, without marked changes in medication anticipated for the duration of the study.
  • Body weight ≥ 45 kilogram (kg) to less than or equal to (≤)120 kg with (BMI) between 17 and 34.9 kilogram per meter square (kg/m\^2), inclusive.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of follows requirements outlined in the protocol
  • A male participant is eligible to participate if he follows contraception requirements outlined in the protocol
  • Willing and able to give which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Availability of an adult person who has frequent and sufficient contact with the participant is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the ICF of the study partner.

Exclusion criteria

Exclusion Criteria:

Participant has evidence of any neurological condition other than AD that may contribute to cognitive impairment.

  • History or presence of vascular disease that has the potential to affect cognitive function.
  • History or presence of stroke within the past 1 year or recent within 180 days before screening.
  • History of severe, central nervous system (CNS) trauma.
  • History or presence of intracranial tumor.
  • Presence of ongoing infection(s) that may affect brain function, or history of infections that resulted in neurologic sequelae.
  • History of primary psychiatric diagnosis that the investigator considers may interfere with study assessments.

Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, suicidal behaviour or has been assessed to be at risk of suicide, in the opinion of the investigator within 6 months before screening, at screening, or at the Baseline visit, or has been hospitalized or treated for suicidal behaviour in the past 2 years.

  • Participant has history of alcohol and/or moderate to severe substance use disorder within the past 2 years
  • Magnetic resonance imaging (MRI) evidence based on central read of:

    1. >3 lacunar infarcts.
    2. Stroke involving a major vascular territory, severe small vessel, or white matter disease.
    3. Any territorial /cortical/other infarct >1 cubic centimetre (cm\^3).
    4. White matter hyperintense lesions on the FLAIR sequence that correspond to an overall Fazekas score of 3
    5. >4 microhaemorrhages.
    6. Any areas of superficial () hemosiderosis.
    7. A single macro-hemorrhage greater than 10 millimetres (mm) at greatest diameter.
    8. Vasogenic edema.
    9. Cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions.
    10. Space occupying lesions or brain tumors.
    11. Significant cerebral vascular pathology
    12. Hydrocephalus/Normal pressure hydrocephalus.
    13. Other MRI findings contraindicating participation in the study such as subarachnoid hemorrhage.
  • History suggestive of exposure to, or past tuberculosis (TB) infection should undergo screening for TB disease.
  • Chronic active immune disorder requiring systemic therapy within 6 months prior to Screening.
  • Screening serum vitamin B12 concentration \< Lower limit of normal (LLN) or in the low normal range
  • Folate \<LLN or Thyroid-stimulating hormone (TSH) > (ULN)
  • >8 percentage (%) or poorly controlled diabetes during the last 12 weeks
  • History of cancer
  • Known history of severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Planned surgery during the study which requires general, spinal, or epidural anesthesia that would take place during the study.
  • Known genetic predisposition for clotting disorder or hemorrhagic disease.
  • Key exclusionary medications include:

    • Antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood stabilizers, or stimulants that are used on a chronic basis, are exclusionary if not consistent with the following rule: treatment has to have been at a stable dose for at least 4 weeks before screening and should remain stable during the study
    • Any biologic drugs with systemic exposure, whether or approved, used within 6 months before screening Any disease modification drug for AD, such as aducanumab and lecanemab, whether investigational or approved, used within 6 months before screening.
    • Anticoagulation medications within 90 days of screening and during the study
    • Systemic immunosuppressive therapy within 6 months before screening and during the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
367 participants (actual)

Study arms

  • Experimental
    GSK4527226 Dose 1

    Participants will receive GSK4527226 Dose 1

    Drug: GSK4527226

  • Experimental
    GSK4527226 Dose 2

    Participants will receive GSK4527226 Dose 2

    Drug: GSK4527226

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Other: Placebo

Interventions

  • DrugGSK4527226

    GSK4527226 will be administered.

  • OtherPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The CDR-SB score is a quantitative general index that provides more precision in participants with mild dementia. The CDR scale is a clinician-rated dementia staging system tracks the progression of. cognitive impairment in 6 categories (memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5- point scale in which None=0, Questionable=0.5, Mild=1, Moderate=2, and Severe=3. The CDR-SB is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.

    Time frame: Baseline, Week 52, 64 and 76

Secondary outcomes

  1. Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The iADRS is a composite score that measures both cognition and function. The iADRS comprises scores from the AD Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimers Disease Cooperative Study-instrumental Activities of Daily Living (ADCS-iADL). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog14 (14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. Higher scores indicate greater impairment) and the ADCS-iADL (score range from 0-49 with higher scores reflecting better performance and lower scores indicating greater functional impairment).

    Time frame: Baseline, Weeks 52, 64 and 76

  2. Change from Baseline in ADAS-Cog14 Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The AD Assessment Scale-Cognitive subscale (ADAS-Cog14) is a 14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. Score ranges from 0 to 90 and higher scores indicate greater impairment.

    Time frame: Baseline, Weeks 52, 64 and 76

  3. Change from Baseline in ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The AD Cooperative Study - Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-ADL-MCI). The ADCS-ADL for MCI is a 23-item scale that measures the competence of participants in basic and instrumental activities of daily living. Total scores on the ADCS-ADL-MCI range from 0 to 53 where lower scores indicates greater functional impairment.

    Time frame: Baseline, Weeks 52, 64 and 76

  4. Change from Baseline in ADCS-iADL component of ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The ADCS-iADL is a subscale which measures instrumental activities of daily living. The ADCS-iADL is derived from the ADCS-ADL-MCI. It has a total score ranging from 0 to 49 with lower scores indicating greater functional impairment.

    Time frame: Baseline, Weeks 52, 64 and 76

  5. Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) for Dose 1 vs Placebo Across Weeks 52, 64 and 76

    The ADCOMS is a composite score comprising scores from various items of the Mini-Mental Status Examination (MMSE), ADAS-Cog14, and CDR domains. The MMSE is a brief test used to screen for cognitive impairment. It is routinely used for estimating the severity of cognitive impairment and tracking cognitive changes in an individual over time. It assesses orientation (time and place), registration, attention and calculation, recent memory, language (naming, comprehension, and repetition), and constructional praxis (copying a figure). For ADCOMS a higher score is indicative of greater impairment.

    Time frame: Baseline, Weeks 52, 64 and 76

07

Study locations

97 sites
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    Lake Mary, Florida 32720, United States
  • GSK Investigational Site
    Lake Worth, Florida 33462, United States
  • GSK Investigational Site
    Maitland, Florida 32752, United States
  • GSK Investigational Site
    Miami, Florida 33176-7947, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Stuart, Florida 34997, United States
  • GSK Investigational Site
    The Villages, Florida 32159, United States
  • GSK Investigational Site
    The Villages, Florida 32162, United States
  • GSK Investigational Site
    Decatur, Georgia 30030, United States
  • GSK Investigational Site
    Elk Grove Village, Illinois 60007, United States
  • GSK Investigational Site
    Chesterfield, Missouri 63005, United States
  • GSK Investigational Site
    Toms River, New Jersey 08755-5043, United States
  • GSK Investigational Site
    Staten Island, New York 10314, United States
  • GSK Investigational Site
    Matthews, North Carolina 28105-8335, United States
  • GSK Investigational Site
    North Canton, Ohio 44720, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • GSK Investigational Site
    Portland, Oregon 97210-5311, United States
  • GSK Investigational Site
    Houston, Texas 77030-1312, United States
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    Buenos Aires, C1428AQK, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1431FWO, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABJ, Argentina
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Kogarah, New South Wales 2217, Australia
  • GSK Investigational Site
    Macquarie Park, New South Wales 2113, Australia
  • GSK Investigational Site
    Gold Coast, Queensland 4222, Australia
  • GSK Investigational Site
    Heidelberg, Victoria 3079, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Melbourne, Australia
  • GSK Investigational Site
    Ottawa, Ontario K1Z 1G3, Canada
  • GSK Investigational Site
    Peterborough, Ontario K9H 2P4, Canada
  • GSK Investigational Site
    Toronto, Ontario M3B 2S7, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2J2, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    Helsinki, 00180, Finland
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Oulu, 90100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Bron, 69500, France
  • GSK Investigational Site
    Lille, 59037, France
  • GSK Investigational Site
    Nice, 06100, France
  • GSK Investigational Site
    Paris, 75010, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Saint-Herblain, 44093, France
  • GSK Investigational Site
    Strasbourg, 67000, France
  • GSK Investigational Site
    Toulouse, 31300, France
  • GSK Investigational Site
    Villeurbanne, 69100, France
  • GSK Investigational Site
    Erbach im Odenwald, Hesse 64711, Germany
  • GSK Investigational Site
    Cologne, 50935, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Münster, 48149, Germany
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    CefalU PA, 90015, Italy
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Milan, 20132, Italy
  • GSK Investigational Site
    Milan, 20133, Italy
  • GSK Investigational Site
    Modena, 41126, Italy
  • GSK Investigational Site
    Monza, 20900, Italy
  • GSK Investigational Site
    Pavia, 27100, Italy
  • GSK Investigational Site
    Perugia, 06129, Italy
  • GSK Investigational Site
    's-Hertogenbosch, North Brabant 5223 LA, Netherlands
  • GSK Investigational Site
    Amsterdam, North Holland 1081 GN, Netherlands
  • GSK Investigational Site
    Zwolle, Overijssel 8025 AZ, Netherlands
  • GSK Investigational Site
    Bergen, 5009, Norway
  • GSK Investigational Site
    Oslo, 0450, Norway
  • GSK Investigational Site
    Stavanger, Norway
  • GSK Investigational Site
    Junggu, 400711, South Korea
  • GSK Investigational Site
    Seoul, 04763, South Korea
  • GSK Investigational Site
    Seoul, 138-736, South Korea
  • GSK Investigational Site
    Pozuelo de Alarcón, Madrid 28223, Spain
  • GSK Investigational Site
    Getxo, Vizcaya 48993, Spain
  • GSK Investigational Site
    Barcelona, 08028, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
  • GSK Investigational Site
    Terrassa - Barcelona, 08221, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Gothenburg, 431 41, Sweden
  • GSK Investigational Site
    Malmö, 21146, Sweden
  • GSK Investigational Site
    Stockholm, Sweden
  • GSK Investigational Site
    Kaohsiung City, 833, Taiwan
  • GSK Investigational Site
    Tainan, 704, Taiwan
  • GSK Investigational Site
    Tau-Yuan, 333, Taiwan
  • GSK Investigational Site
    Ankara, 06230, Turkey (Türkiye)
  • GSK Investigational Site
    CapaIstanbul, 34093, Turkey (Türkiye)
  • GSK Investigational Site
    Birmingham, B16 8LT, United Kingdom
  • GSK Investigational Site
    Bristol, BS32 4SY, United Kingdom
  • GSK Investigational Site
    Glasgow, ML1 4UF, United Kingdom
  • GSK Investigational Site
    London, EC2Y 8EA, United Kingdom
  • GSK Investigational Site
    London, W1G 8TA, United Kingdom
  • GSK Investigational Site
    London, WC1N 3BG, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in May 2026, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2023
First posted
Oct 12, 2023
StartActual
Oct 20, 2023
Primary completionActual
May 14, 2026
CompletionActual
Aug 18, 2026
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06079190
Lead sponsor
GlaxoSmithKline
Collaborators
Alector Inc.
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Oct 20, 2023
Primary completion
May 14, 2026
Completion
Aug 18, 2026
Last update
Sep 17, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion